亚砷酸对JAK2V617F阳性的骨髓增殖性肿瘤的影响

The influence of arsenic trioxide in treatment of JAK2V617F positive myoloprolifera neoplasm

目的:探讨亚砷酸(arsenic trioxide,ATO)在治疗JAK2V617F突变阳性的骨髓增殖性疾病(myelopro-liferative neoplasm,MPN)中的作用。方法:选取20例JAK2V617F阳性的MPN患者用亚砷酸治疗,观察其治疗前后不同时期相应的血象变化以及JAK2V617F表达,并与单用羟基脲的对照组作比较。结果:与对照组相比,3个月及1年后,应用亚砷酸治疗组的红细胞、血红蛋白、血小板、白细胞均明显降低(P<0.01);治疗3年后两组上述指标无明显差异(P>0.05);JAK2V617F的转阴率两组无明显差异性(P>0.05)。结论:亚砷酸作为一种诱导凋亡剂短期内可以有效地降低三系血细胞,但未有证据表明能降低MPN患者JAK2V617F的阳性表达,故长期疗效需更多的临床及实验观察。

Objective：To evaluate the treatment effect of arsenic trioxide （ATO） in JAK2V617F positive myelo- proliferative neoplasm （MPN） patients. Methods：Twenty cases with JAK2V617F positive MPD patients were treated with arsenic trioxide, compared with the control group treated with hydroxyurea. The hemogram and the expression levels of JAK2V617F were evaluated before and after the treatment. Results：The average red blood cell, white blood cell, platelets were significantly decreased in 3 months, 1 year after treated with arsenic trioxide, compared with the control group（P 〈0.01 ）. No significant hemogram changes were found in 3 years after treatment （P 〉 0.05） be- tween the two groups. No obvious difference in JAK2V617F negative conversion ratio between the two groups.Conclusion：Arsenic trioxide can decrease the blood count of JAK2V617F positive MPN patients in 1 year, but not in the long time and it cannot reduce the expression level of JAK2V617F.